TFAP2B and Char syndrome: Therefore, although it is too early to present TFAP2B as a new CIPO gene since only one patient has been identified, our results suggest that a better characterization of Char syndrome and syndromic craniosynostosis patients is needed, to improve counselling and define optimal treatment strategies.